• Explore /
  • Poster
  • / Bevacizumab (bev) in combination with capecitabine (cape) for the first-line treatment of elderly patients with metastatic colorectal cancer (mCRC): Results of a randomized international phase III trial (AVEX).

Bevacizumab (bev) in combination with capecitabine (cape) for the first-line treatment of elderly patients with metastatic colorectal cancer (mCRC): Results of a randomized international phase III trial (AVEX).

Abstract Poster

Authors

null

David Cunningham

The Royal Marsden Hospital

David Cunningham , Istvan Lang , Vito Lorusso , Janja Ocvirk , Dongbok Shin , Derek Jonker , Stuart Osborne , Niko Andre , Daniel Waterkamp , Mark Saunders

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2013 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session C: Cancers of the Colon and Rectum

Track

Cancers of the Colon, Rectum, and Anus

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

NCT00484939

Citation

J Clin Oncol 31, 2013 (suppl 4; abstr337)

DOI

10.1200/jco.2013.31.4_suppl.337

Abstract #

337

Poster Bd #

A5

Abstract Disclosures

Similar Posters

First Author: Mark P. Saunders

First Author: Clemens Albrecht Giessen

First Author: Zhichao Jiang

First Author: Pilar Garcia-Alfonso